EE52CA48-EBE4-4BCA-B9BA-9AB39F8E7986
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 18.69250985545335
- age_years
- 70
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.447
- UV_RESPONSE_DN+0.377
- TGF_BETA_SIGNALING+0.363
- ANDROGEN_RESPONSE+0.355
- MITOTIC_SPINDLE+0.303
- NOTCH_SIGNALING+0.291
- ANGIOGENESIS+0.220
- IL6_JAK_STAT3_SIGNALING+0.218
- P53_PATHWAY+0.209
- APOPTOSIS+0.187
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.351
- KRAS_SIGNALING_DN-0.333
- SPERMATOGENESIS-0.280
- E2F_TARGETS-0.213
- ESTROGEN_RESPONSE_LATE-0.169
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.153
- UV_RESPONSE_UP-0.143
- MTORC1_SIGNALING-0.125
- G2M_CHECKPOINT-0.115
- XENOBIOTIC_METABOLISM-0.076
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1025 | — | — | 0.746 |
| 2 | MNG461 | — | — | 0.721 |
| 3 | SRR12696759 | — | — | 0.716 |
| 4 | TCGA-86-8055-01A-11R-2241-07 | — | cohortA1 | 0.712 |
| 5 | MDT-AP-0220 | Med | Medulloblastoma | 0.708 |
| 6 | 66A657C4-CC7B-4154-AFAD-342E7CC87EF9 | — | — | 0.707 |
| 7 | R374 | — | — | 0.705 |
| 8 | TCGA-86-8075-01A-11R-2241-07 | — | cohortA1 | 0.704 |
| 9 | ERR2208977 | — | — | 0.704 |
| 10 | SJEPD031786_D1.RNA-Seq | EPN | Anaplastic EPN | 0.695 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.447 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.377 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.363 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.355 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.303 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.291 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.218 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.209 | Idelalisib | — uncovered |
| APOPTOSIS | 0.187 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.177 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.173 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.159 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.157 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.151 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.138 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.135 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.133 | Idelalisib | — uncovered |
| PEROXISOME | 0.119 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.117 | Remibrutinib | — uncovered |